# Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction 56

Study · id `cardio:ct-nct01235351` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01235351](<https://clinicaltrials.gov/study/NCT01235351>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01235351

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 335 participants.

## Technical summary

Registry record NCT01235351. Randomized; quadruple masking; primary purpose treatment. Start 2010-10 (registry gives no type); primary completion 2011-09 (actual). Results posted on 2019-11-15.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 335 participants (enrolled count; ClinicalTrials.gov record NCT01235351, source copy `cardio:ctgov-nct01235351-2019-11-15`, retrieved 2026-10-26)
- Start date: 2010-10 (registry gives no type) (ClinicalTrials.gov record NCT01235351, source copy `cardio:ctgov-nct01235351-2019-11-15`, retrieved 2026-10-26)
- Primary completion: 2011-09 (actual) (ClinicalTrials.gov record NCT01235351, source copy `cardio:ctgov-nct01235351-2019-11-15`, retrieved 2026-10-26)
- Completion: 2011-09 (actual) (ClinicalTrials.gov record NCT01235351, source copy `cardio:ctgov-nct01235351-2019-11-15`, retrieved 2026-10-26)
- Results first posted: 2019-11-15 (ClinicalTrials.gov record NCT01235351, source copy `cardio:ctgov-nct01235351-2019-11-15`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01235351, source copy `cardio:ctgov-nct01235351-2019-11-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01235351-2019-11-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction 56
- Acronym: ELEVATE
- Condition: Myocardial Infarction
- Condition: Percutaneous Coronary Intervention
- Intervention (Drug): Clopidogrel
- Intervention (Drug): Clopidogrel
- Lead sponsor: The TIMI Study Group
- Lead sponsor class: OTHER
- Collaborator: Bristol-Myers Squibb
- Collaborator class: INDUSTRY
- Collaborator: Sanofi
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry intervention is a member of this class by a sourced record link: P2Y12 inhibitors (drug class) (`cardio:p2y12-inhibitors`)
- Registry lists this organization as the lead sponsor: The TIMI Study Group (`cardio:org-the-timi-study-group`)
- Registry lists this organization as a collaborator: Bristol-Myers Squibb (`cardio:org-bristol-myers-squibb`)
- Registry lists this organization as a collaborator: Sanofi (`cardio:org-sanofi`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease (`cardio:pubmed-22088980`)
- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trial (`cardio:pubmed-25060370`)
- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial (`cardio:pubmed-27009617`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 24eaf4da389ac0b1c04f8d9b2e0d7b6c41c7ab1cb9b948fd81dded6e2bc78552
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
